Renaissance Technologies
NVIV

Renaissance Technologies’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Renaissance Technologies’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-13,921
Closed -$16K – 4307
2023
Q3 		$16K Sell
13,921
-3,345
-19% -$4.16K ﹤0.01% 3551
2023
Q2 		$23K Buy
17,266
+6,241
+57% +$7.94K ﹤0.01% 3753
2023
Q1 		$12K Buy
11,025
+900
+9% +$1.71K ﹤0.01% 3878
2022
Q4 		$24K Sell
10,125
-17,600
-63% -$44.1K ﹤0.01% 3940
2022
Q3 		$119K Buy
+27,725
New +$152K ﹤0.01% 3537
2022
Q2 		– Sell
-3,172
Closed -$27K – 4727
2022
Q1 		$27K Buy
3,172
+1,916
+153% +$18.2K ﹤0.01% 3985
2021
Q4 		$14K Buy
+1,256
New +$18K ﹤0.01% 3853
2021
Q3 		– Sell
-21,207
Closed -$394K – 4054
2021
Q2 		$394K Buy
21,207
+4,600
+28% +$87.6K ﹤0.01% 3060
2021
Q1 		$413K Buy
16,607
+12,148
+272% +$364K ﹤0.01% 2981
2020
Q4 		$90K Buy
+4,459
New +$87.3K ﹤0.01% 3264
2020
Q3 		– Sell
-3,729
Closed -$147K – 3866
2020
Q2 		$147K Buy
3,729
+1,874
+101% +$73K ﹤0.01% 3216
2020
Q1 		$78K Buy
1,855
+873
+89% +$124K ﹤0.01% 3269
2019
Q4 		$166K Buy
982
+340
+53% +$84.5K ﹤0.01% 3229
2019
Q3 		$241K Buy
642
+59
+10% +$27.7K ﹤0.01% 3093
2019
Q2 		$324K Buy
583
+75
+15% +$65.9K ﹤0.01% 3150
2019
Q1 		$591K Buy
508
+25
+5% +$29K ﹤0.01% 2873
2018
Q4 		$547K Buy
483
+167
+53% +$242K ﹤0.01% 2830
2018
Q3 		$478K Buy
316
+150
+90% +$221K ﹤0.01% 2860
2018
Q2 		$211K Buy
166
+157
+1,744% +$861K ﹤0.01% 3063
2018
Q1 		$86K Buy
+9
New +$101K ﹤0.01% 3273
2016
Q2 		– Sell
-2
Closed -$221K – 3641
2016
Q1 		$221K Buy
+2
New +$215K ﹤0.01% 3053

Other funds holding NVIV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return
CTA
Colonial Trust Advisors Spartanburg, South Carolina $1.29B AUM 19.9% 1-Year Est. Return
ITIM
Indiana Trust & Investment Management Mishawaka, Indiana $366M AUM 33.66% 1-Year Est. Return

Renaissance Technologies's NVIV Position: Q4 2023 in Review

Renaissance Technologies sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q4 2023, closing a stake of 13,921 shares — an estimated $16K sold.

Renaissance Technologies first reported a position in NVIV in Q1 2016 and held it in 21 quarters. The position peaked at $591K in Q1 2019. 14 funds tracked by Wall St. Rank hold NVIV as of Q4 2023.

  • Renaissance Technologies reported no remaining InVivo Therapeutics Holdings Corp position as of Q4 2023 after selling out during the quarter.
  • Renaissance Technologies sold 13,921 InVivo Therapeutics Holdings Corp shares in Q4 2023, an estimated $16K.
  • Renaissance Technologies first reported a position in InVivo Therapeutics Holdings Corp in Q1 2016 and held it in 21 quarters.
  • Renaissance Technologies's InVivo Therapeutics Holdings Corp position peaked at $591K in Q1 2019.
  • 14 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q4 2023.

Based on Renaissance Technologies's 13F filing for Q4 2023, filed 13 Feb 2024.